As Direct-to-Patient (DTP) and its closely related cousin Direct-to-Employer (DTE) continue gaining traction in the general medicine market, manufacturers are increasingly asking us a variation of the same question.

"We understand why Direct-to-Patient has emerged for primary care and general medicine products. But does it have a future in specialty pharmaceuticals?"

It is a fair question. But there may be a more provocative question manufacturers should be asking.

What if insurance is no longer the most efficient way to buy pharmaceuticals?

For decades, the pharmaceutical industry operated under a simple assumption. Commercial insurance, government programs, PBMs, health plans, specialty pharmacies, and retail pharmacies represented the most efficient path between manufacturers and patients. While manufacturers competed aggressively for formulary position, few questioned the underlying channel itself.

Today, that assumption is being challenged. 

What began as isolated cash-pay programs for low-cost generics has evolved into a legitimate commercialization model supported by telehealth platforms, digital pharmacies, manufacturer-sponsored programs, transparent pricing models, and increasingly informed consumers. More importantly, patients and employers are beginning to discover that the insured channel is not always the lowest-cost channel.

The early evidence is difficult to ignore. 

Generic therapies such as imatinib (Gleevec®) and abiraterone (Zytiga®) can generate tens of thousands of dollars in annual drug spend when processed through traditional insurance channels, yet generic versions can be purchased through cash pharmacies for only a few hundred dollars per year. In many situations, the cash price available directly to consumers is materially lower than the fully adjudicated cost borne by plan sponsors and ultimately patients.

Recent research published in AJMC reinforces this trend. Among prescriptions where commercially insured patients faced copays greater than $15, Cost Plus Drugs offered lower pricing approximately 82% of the time. Once patient cost-sharing becomes meaningful, cash channels become surprisingly competitive alternatives to traditional insurance.

This phenomenon is no longer limited to traditional generics. 

As the industry enters the front edge of a projected $225 billion specialty patent cliff, many of the same economic forces are beginning to emerge within specialty pharmaceuticals. Manufacturers and biosimilar competitors are experimenting with cash-pay offerings for products such as adalimumab (Humira®) and ustekinumab (Stelara®). AbbVie itself introduced direct cash-pay options for Humira as biosimilar competition accelerated. These moves would have been almost unthinkable five years ago.

The significance of these developments extends far beyond individual products. They signal the emergence of a third pharmaceutical economy.

Historically, manufacturers operated within two primary markets: commercial insurance and government programs. Today, a third market has emerged- self-pay. Enabled by telehealth, digital pharmacies, transparent pricing, employer purchasing strategies, and consumer choice, self-pay is becoming a legitimate channel strategy rather than simply a fallback option for uninsured patients.

This shift is occurring simultaneously with several powerful industry trends:

• A looming wave of specialty loss-of-exclusivity events
• Continued deterioration of gross-to-net performance in highly competitive specialty classes such as immunology
• PBMs increasingly limiting formulary access to one or two preferred biosimilars despite numerous market entrants
• Therapeutic classes where ten or more manufacturers may compete for limited formulary positions
• Growing awareness among patients and self-funded employers that insurance is not always the lowest-cost option
• The maturation of DTP and DTE platforms capable of acquiring, prescribing, dispensing, and servicing patients directly

Taken together, these forces raise an important strategic question.

If direct-to-patient has already become a viable commercialization model for general medicine products, under what circumstances does it become relevant for specialty pharmaceuticals?

That is the question manufacturers should be evaluating today. The answer is not that every specialty product belongs in a DTP model. Most do not. But a growing subset of specialty therapies subjected to MFP and LOE now exhibit the same economic and channel characteristics that previously drove DTP adoption in general medicine. Understanding which products fit those characteristics is becoming an increasingly important component of commercialization strategy.

And there may be an even bigger question lurking beneath the surface.

If patients and employers increasingly discover that cash can be cheaper than insurance, and if PBMs continue limiting access to only a handful of preferred specialty competitors, are we approaching a future where channel strategy becomes just as important as formulary strategy? For the 1400 NDCs currently blocked and any product standing behind a rigorous set of prior authorizations, egregious step edits and patients in high-deductible plans, the answer is pretty obvious. That possibility may sound provocative today. Five years from now, it may simply be reality.

About IntegriChain

IntegriChain delivers biopharma’s only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls.

Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, contact us or follow us on LinkedIn.